Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Stock Picking - 2003 -- Ignore unavailable to you. Want to Upgrade?

To: scott_jiminez who wrote (51)	1/3/2003 9:46:03 PM
From: Harold Engstrom	Respond to of 383

OT (again) - Lilly, Pfizer, and Merck & Co, (and especially Wyeth) have biopharm components but are pharmaceutical companies due to the fact that their revenues are almost entirely derived from products manufactured chemically and not biologically. Amgen's revenues (EPO, Neupo, Enbrel) come from biologics. Perhaps a small percentage of products are manufactured chemically. Biopharms are defined by this (IMO.) Not sure I agree that, "'cells" have been used by pharmas decades before the word 'biotech' was even coined." But I am not sure that even matters. No one I know has ever refered to Sepracor as a biotech company - or referred to Pfizer et al as such (even after Pfizer swallowed Auguron). I do not know of anyone that calls Amgen a pharma. In fact there are distinct codes of the Code of Federal Regulations that deals with each type of business - pharma (300 series), biopharma (600 series) and medical devices (900 series). This is totally unimportant and if this were the 6th of Jan instead of the 3rd, then I wouldn't even have time to bs about this, but there are my last 2 cents on the matter!